Europe
Brisbane biotech Microba were chosen to participate in international pitching competition, the Falling Walls Venture in Berlin, based on their world-leading work in analysing gut bacteria.
MorphoSys AG announced that its licensee Novartis presented phase 2 results for bimagrumab, a human anti-activin receptor monoclonal antibody developed by Novartis and generated utilizing MorphoSys’s proprietary HuCAL antibody technology.
The bioregion is from until November 13 participating at the 25th Annual International Partnering Conference BIO-Europe 2019 in Hamburg.
Evgen Pharma, a clinical stage drug development company focused on the treatment of cancer and neurological conditions, provides the following clarification
The experimental drug, if approved, will compete with GlaxoSmithKline’s Benlysta, which is the only new drug approved for lupus in the last 60 years.
Heidelberg Pharma AG announced that its partner Magenta Therapeutics, Cambridge, MA, USA, declared that it will exercise the option for the exclusive worldwide development and marketing rights for Antibody Targeted Amanitin Conjugates targeting CD45.
London: Monday, November 11, 2019: Hutchison China MediTech Limited announces that Christian Hogg, Chief Executive Officer, will present at the following conferences
Ubiquigent Limited and LEO Pharma A/S announced that they have entered into an option agreement granting LEO Pharma access to two novel compounds.
ORYX, a translational medicine company focused on oncolytic virotherapy and cancer vaccines, reported new results on the mode of action of oncolytic virus ParvOryx in human ovarian cancer explants.
Lytix Biopharma AS announces a clinical collaboration with the US-based company Iovance Biotherapeutics, Inc., a late-stage biotechnology company developing novel cancer immunotherapies based on tumor infiltrating lymphocyte technology, to evaluate Lytix`s first-in-class oncolytic peptide, LTX-315, in combination with Iovance`s autologous ready to infuse T cell therapy.
PRESS RELEASES